# FATE THERAPEUTICS INC (FATE) · Edgar & Edgarette company card

> Fate Therapeutics (FATE) saw revenue fall 51.2% in FY2025 to $7 million, operating margin -2222% against a -15.8% median for biological products, (no diagnostic substances), equity 65.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1434316 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/FATE) · [JSON](https://www.pops4.com/boards/company/FATE.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $7M |
| Revenue growth, 1 year | -51.2% |
| Revenue growth per year | -41.3% |
| Operating margin | -2222.4% (prior year -1542.6%) |
| Net margin | -2051.1% |
| Operating cash flow | −$106M |
| Capital spending | $6M |
| Free cash flow | −$112M |
| Cash | $47M |
| Long-term debt | — |
| Total assets | $319M |
| Total equity | $207M |
| Equity ÷ assets | 65.0% |
| Return on equity | -65.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -13.3 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -2222.4% in FY2025; revenue is hard to predict: its 80% range is ±83%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $6.6M (FY2025). Experience: revenue down 51.2% on the year, down 41.3% a year over 4 years; operating margin -2222.4%, down from -1542.6%. Soundness: equity 65.0% of assets, return on equity -65.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $915K and $9.6M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $779K to $11.3M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -2222.4% against a -15.8% median; growth -51.2% against 21.4%.

Range logged 2026-11-06, receipt 66265aa5c04de4c8, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-06-15 ([filing](https://www.sec.gov/Archives/edgar/data/1434316/000119312526271055/0001193125-26-271055-index.htm))

## Recent filings

- 8-K · filed 2026-11-05 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1434316/000119312526449840/0001193125-26-449840-index.htm)
- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1434316/000119312526448543/0001193125-26-448543-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1434316/000119312526448530/0001193125-26-448530-index.htm)
- 8-K · filed 2026-09-28 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1434316/000119312526403429/0001193125-26-403429-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1434316/000119312526347988/0001193125-26-347988-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1434316/000119312526347984/0001193125-26-347984-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001434316.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1434316

## Cite

POPS4, Edgar & Edgarette: FATE THERAPEUTICS INC (FATE) company card, from the company's own SEC filings, accessed 2026-11-06, https://www.pops4.com/boards/company/FATE. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.